306 related articles for article (PubMed ID: 11453952)
1. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
Kaltsas GA; Mukherjee JJ; Isidori A; Kola B; Plowman PN; Monson JP; Grossman AB; Besser GM
Clin Endocrinol (Oxf); 2002 Aug; 57(2):169-83. PubMed ID: 12153595
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response.
Buscombe JR; Cwikla JB; Caplin ME; Hilson AJ
Nucl Med Commun; 2005 Nov; 26(11):969-76. PubMed ID: 16208174
[TBL] [Abstract][Full Text] [Related]
4. Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre.
Rutherford MA; Rankin AJ; Yates TM; Mark PB; Perry CG; Reed NS; Freel EM
QJM; 2015 May; 108(5):361-8. PubMed ID: 25267727
[TBL] [Abstract][Full Text] [Related]
5. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.
Gedik GK; Hoefnagel CA; Bais E; Olmos RA
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):725-33. PubMed ID: 18071700
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors.
Ezziddin S; Sabet A; Logvinski T; Alkawaldeh K; Yong-Hing CJ; Ahmadzadehfar H; Grünwald F; Biersack HJ
J Nucl Med; 2013 Dec; 54(12):2032-8. PubMed ID: 24101685
[TBL] [Abstract][Full Text] [Related]
7. Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy.
Bomanji JB; Wong W; Gaze MN; Cassoni A; Waddington W; Solano J; Ell PJ
Clin Oncol (R Coll Radiol); 2003 Jun; 15(4):193-8. PubMed ID: 12846498
[TBL] [Abstract][Full Text] [Related]
8. Radioiodinated metaiodobenzylguanidine treatment of neuroendocrine tumors in adults.
Postema EJ; McEwan AJ
Cancer Biother Radiopharm; 2009 Oct; 24(5):519-25. PubMed ID: 19877881
[TBL] [Abstract][Full Text] [Related]
9. Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131I-metaiodobenzylguanidine.
Bomanji J; Britton KE; Ur E; Hawkins L; Grossman AB; Besser GM
Nucl Med Commun; 1993 Oct; 14(10):856-61. PubMed ID: 8233228
[TBL] [Abstract][Full Text] [Related]
10. ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.
Bomanji JB; Papathanasiou ND
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S113-25. PubMed ID: 22388626
[TBL] [Abstract][Full Text] [Related]
11. 131I-MIBG therapy of neural crest tumours (review).
Troncone L; Rufini V
Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
[TBL] [Abstract][Full Text] [Related]
12. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
Castellani MR; Chiti A; Seregni E; Bombardieri E
Q J Nucl Med; 2000 Mar; 44(1):77-87. PubMed ID: 10932604
[TBL] [Abstract][Full Text] [Related]
13. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.
Loh KC; Fitzgerald PA; Matthay KK; Yeo PP; Price DC
J Endocrinol Invest; 1997 Dec; 20(11):648-58. PubMed ID: 9492103
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
Gonias S; Goldsby R; Matthay KK; Hawkins R; Price D; Huberty J; Damon L; Linker C; Sznewajs A; Shiboski S; Fitzgerald P
J Clin Oncol; 2009 Sep; 27(25):4162-8. PubMed ID: 19636009
[TBL] [Abstract][Full Text] [Related]
15. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans.
Monsieurs M; Brans B; Bacher K; Dierckx R; Thierens H
Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1581-7. PubMed ID: 12458391
[TBL] [Abstract][Full Text] [Related]
16. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma.
Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman JM; Leight GS; Tyler DS; Olson JA
Surgery; 2003 Dec; 134(6):956-62; discussion 962-3. PubMed ID: 14668728
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of (131)Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders.
Mulholland N; Chakravartty R; Devlin L; Kalogianni E; Corcoran B; Vivian G
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2002-12. PubMed ID: 26142730
[TBL] [Abstract][Full Text] [Related]
18. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG.
Thorpe MP; Kane A; Zhu J; Morse MA; Wong T; Borges-Neto S
J Clin Endocrinol Metab; 2020 Mar; 105(3):e494-501. PubMed ID: 31614368
[TBL] [Abstract][Full Text] [Related]
20. Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma.
Wakabayashi H; Taki J; Inaki A; Nakamura A; Kayano D; Fukuoka M; Matsuo S; Nakajima K; Kinuya S
Ann Nucl Med; 2013 Nov; 27(9):839-46. PubMed ID: 23864328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
